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Abstract
There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especially post-
myeloproliferative neoplasm (MPN) secondary (s) AML. Studies presented describe effects of genetic knockout,
degradation or small molecule targeted-inhibition of GFI1/LSD1 on active enhancers, altering gene-expressions and
inducing differentiation and lethality in AML and (MPN) sAML cells. A protein domain-focused CRISPR screen in LSD1
(KDM1A) inhibitor (i) treated AML cells, identified BRD4, MOZ, HDAC3 and DOT1L among the codependencies. Our
findings demonstrate that co-targeting LSD1 and one of these co-dependencies exerted synergistic in vitro lethality in
AML and post-MPN sAML cells. Co-treatment with LSD1i and the JAKi ruxolitinib was also synergistically lethal against
post-MPN sAML cells. LSD1i pre-treatment induced GFI1, PU.1 and CEBPα but depleted c-Myc, overcoming nongenetic
resistance to ruxolitinib, or to BETi in post-MPN sAML cells. Co-treatment with LSD1i and BETi or ruxolitinib exerted
superior in vivo efficacy against post-MPN sAML cells. These findings highlight LSD1i-based combinations that merit
testing for clinical efficacy, especially to overcome nongenetic therapy-resistance in AML and post-MPN sAML.
Introduction
During complete remission in AML, AML stem/pro-
genitor cells (LSCs) in the measurable residual disease
(MRD) resist differentiation, retain leukemia-initiating
potential and mediate relapse of AML1–3. This pheno-
type of LSCs is mainly orchestrated by dysregulated super-
enhancers (SEs)/enhancers (Es) and the ensuing dysregu-
lated transcriptome/proteome, which directly results from
genetic alterations and/or perturbed levels and activity of
epigenetic and transcriptional regulators in AML4–6. SEs/
Es of myeloid lineage transcription factors (TFs) and of
their target genes in AML LSCs are characterized by his-
tone H3 lysine (K) 27 acetyl (H3K27Ac) and H3K4 mono-
methylation (H3K4Me1) marks, as well as by high occu-
pancy with BRD4 and histone acetyl transferase CBP/
p3007–9. Among the key LSC-specific TFs that regulate
cell growth, differentiation and survival of AML stem cell
differentiation are RUNX1, PU.1, CEBPα, c-Myb, and c-
Myc10–13. LSD1 (lysine specific demethylase 1; KDM1A) is
a FAD-dependent amine-oxidase family member and a
component of the co-repressor complexes involving
HDAC1/2 and CoREST (RCOR1) or NuRD (MTA2)14.
LSD1 contains a conserved N-terminal SWIRM domain
(100 AA) and C-terminal amine oxidase-like (AOL) cata-
lytic domain14,15. The AOL domain binds to FAD and the
methylated H3K4 substrate, causing demethylation of
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mono and dimethyl histone H3 lysine 4 (H3K4Me1 and
H3K4Me2)15,16. Two antiparallel α-helices divide and
project away from the AOL domain as the Tower domain,
which provides the binding interface with CoREST
(RCOR1 and HDAC1/2) and allosterically regulates the
catalytic activity and stability of LSD114–16. In addition to
H3K4, LSD1 also demethylates TP53, E2F1, and
DNMT117,18. LSD1 interacts with GFI1/1B, a zinc finger
transcriptional repressor and master regulator of normal
and malignant lineage development and differentiation in
hematopoiesis18–21. GFI1/1B contains an N-terminal, 20
AA SNAG domain and six C-terminal Zn fingers22. LSD1
binds to the methylated lysine in the 8KSKK11 motif in the
SNAG (Snail/GFI1) domain, and thereby helps recruit
RCOR1-HDAC1/2 co-repressor complex to mediate
transcriptional repression and differentiation block due to
GFI1 activity in AML stem/progenitor cells19–22. GFI1/1B
can be co-immunoprecipitated with LSD1 and CoREST
and exhibits overlapping DNA-binding sites at enhancers
(by ChIP-Seq analyses) of key myeloid/monocyte
differentiation–regulatory genes21,23. LSD1 inhibitors
(LSD1i) disrupt GFI1/1B interaction with LSD1-CoREST,
inducing differentiation of AML blast progenitor
cells17,21,23–25. Importantly, CRISPR-suppressor scanning
revealed that enzymatic activity of LSD1 was not required
for blocked AML differentiation and survival26. GFI1/1B
interaction with LSD1 and CoREST also causes deme-
thylation of K372 on TP53, thereby inactivating TP5317,21.
Notably, LSD1 is over-expressed in the stem/progenitor
versus differentiated sub-types of AML17,21, and GFI1
expression is a documented prognostic factor in MDS/
AML27. LSD1i treatment also increased chromatin acces-
sibility and binding of SPI1 and CEBPα at their target Es/
promoters28. Knockdown by shRNA or treatment with
either the irreversible tranylcypromine (TCP)-derivative
LSD1i or the reversible LSD1i SP2509 disrupted LSD1-
binding to CoREST and GFI1/1B, induce differentiation
markers (CD86 and CD11b) and morphologic differ-
entiation, repress colony growth, as well as sensitize AML
blast progenitor cells (BPCs) to all-trans retinoic acid
(ATRA)23,25,29–32. Co-treatment with LSD1i and cytar-
abine, DNA hypomethylating agents, or inhibitor of
HDACs, FLT3, DOT1L or BCL2, was shown to exert
synergistic lethality in AML expressing MLL fusion pro-
tein25,30. However, these studies did not interrogate the
activity of LSD1i and LSD1i-based combinations in post-
MPN sAML blast progenitor cells (BPCs). In present
studies, utilizing for the first time CRISPR-Cas9, or LSD1-
FKBP12F36V and dTAG-13, we demonstrate that knockout
(KO) or degradation of LSD1 inhibits growth and induces
differentiation of AML BPCs with or without expression of
MLL fusion oncoproteins, and of post-MPN sAML BPCs.
While disrupting the binding of LSD1 to CoREST and
GFI1, treatment with irreversible LSD1i also attenuated c-
Myc levels, but induced expressions of GFI1, PU.1, p21,
and CD11b, inhibiting in vitro growth, inducing differ-
entiation/cell lethality, as well as extending survival in
immune-depleted mice engrafted with AML or sAML.
Utilizing a domain-focused CRISPR-Cas9 sgRNA screen
followed by LSD1i treatment, present studies also
demonstrate co-dependencies, including BRD4, in AML
cells. Whereas co-treatment with an LSD1i and BETi
(OTX015) synergistically induced lethality in PD AML
including sAML BPCs, pre-treatment with LSD1i sensi-
tized JAKi-resistant post-MPN sAML cells to ruxolitinib
and BETi P/R cells to BETi-induced apoptosis33. Co-
treatment with LSD1i and BETi (OTX015) also inhibited
AML cell burden and improved median survival of NSG
mice engrafted with AML or post-MPN sAML cells.
Results
Biologic effects of CRISPR-Cas9-mediated LSD1 knockout
or dTAG-13-mediated degradation of LSD1 in AML cells
We first determined effects of CRISPR-Cas9-mediated
knockout (KO) of LSD1 on the CoREST complex and on
GFI1 and its targets in AML OCI-AML5 and post-MPN
sAML SET-2 cells. Fig. 1A demonstrates that 8-days fol-
lowing transduction of two gRNAs targeting exon 2 and 3
of LSD1 into OCI-AML5 cells, stably transduced with
Cas9, LSD1 was profoundly depleted, associated with
reduction in protein levels of CoREST and slightly of
DNMT1, increased GFI1, and unaltered HDAC1/2 and
LSD2 levels. LSD1-KO also attenuated c-Myc levels, while
increasing protein levels of PU.1, CEBPα, p21 and CD11b
(Fig. 1B). Alterations in the levels of these proteins were
associated with decline in % of cells in cell cycle S-phase
and increase in % of G1-phase cells, accompanied by
augmentation in % of cells expressing CD11b that also
displayed morphologic features of differentiation (%
myelocytes and metamyelocytes or bands by morphologic
features of hematoxylin & eosin-stained cytospun cells),
while reducing % of cells expressing c-KIT (Figs. 1C, D
and S1A). LSD1-KO via CRISPR-Cas9 in post-MPN
sAML SET-2 cells, was also accompanied by decline in
the protein levels of LSD1, CoREST, c-Myc, and DNMT1,
but increased protein levels of GF11, PU.1 and CEBPα
(Figs. 1E and S1B). LSD1-KO also inhibited in vitro
growth and increased % of morphologically-differentiated
(% myelocytes and metamyelocytes or bands by mor-
phologic features of hematoxylin & eosin-stained cytos-
pun cells) SET-2 cells with increased CD11b but reduced
c-KIT expression (Figs. 1F, S1C, D), along with significant
increase in % apoptotic cells (Fig. 1G). Following CRISPR-
Cas9-mediated LSD1-KO, perturbed protein expressions
could be documented only 5–8 days later. Therefore, we
employed the dTAG system34 to degrade LSD1-
FKBP12(F36V) in OCI-AML5 cells following knockout of
the endogenous LSD1 to assess within hours loss of LSD1
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and the downstream biological consequences. As shown
in Figs. 1H, S1E–H, 4–24 h after adding dTAG-13, pro-
tein levels of LSD1, CoREST, and c-Myc declined, while
GFI1, PU.1, RUNX1, p21, p27, and CD11b levels were
induced in OCI-AML5 cells. dTAG-13 treatment did not
affect LSD2, HOXA9, and Meis1 levels in OCI-AML5
cells (Figs. S1G, H). Four days after dTAG-13 addition, an
increase in the % of cells expressing CD11b and displaying
morphologic features of differentiation was observed
(Figs. 1I and S1I).
Effect of LSD1 knockout on enhancer activity and
transcriptome in AML cells
Utilizing ChIP-Seq analysis, we next determined the
H3K27Ac signal-density at specific loci in LSD1-KO com-
pared to the control OCI-AML5 cells. Increases in peak-
densities were seen in PU.1 targets, while the peak-densities
decreased on WNT-β-catenin targets (Figs. 2A, B).
H3K27Ac signal-density also decreased at the MYC and
CDK6 loci, whereas ITGAM, LY96, and LYZ gene-loci
demonstrated increased H3K27Ac occupancy (Fig. S2A).
Fig. 1 Knockout of LSD1 by CRISPR/Cas9 depletes c-Myc, and derepresses myeloid differentiation gene CD11b in AML and sAML cells. A, B
Representative immunoblot analysis of OCI-AML5 Cas9- expressing cells transduced with two lentiviral sgRNAs against LSD1 and incubated for
8 days. C Expression of c-Kit and CD11b (assessed by flow cytometry) in OCI-AML5 Cas9 and LSD1 knockout cells 8 days post-transduction. Mean of
two independent experiments performed in duplicate+ S.D. Significance determined by a two-tailed, unpaired t-test. D Morphologic differentiation
(% myelocytes and metamyelocytes or bands by morphologic features of hematoxylin & eosin-stained cytospun cells) of OCI-AML5 Cas9 and LSD1
knockout cells 8 days post-transduction. Mean of two independent experiments performed in duplicate+ S.D. E Representative immunoblot analysis
of SET2 cells transfected with two sgRNAs against LSD1 and incubated for 7 days. F, G Induction of morphologic differentiation (% myelocytes and
metamyelocytes or bands by morphologic features of hematoxylin & eosin-stained cytospun cells) and apoptosis in SET-2 LSD1 knockout cells 7 days
post-transfection. Mean of two independent experiments performed in duplicate+ S.D. **p < 0.01, ***p < 0.005 compared to sgNeg-transfected SET-
2 cells (determined by a two-tailed, unpaired t-test). H Immunoblot analysis of OCI-AML5/LSD1-FKBP12(F36V) cells treated with 500 nM of dTAG-13 for
the indicated times. I OCI-AML5/LSD1-FKBP12(F36V) cells were treated with 500 nM of dTAG-13 for 96 h. At the end of treatment, differentiation was
assessed by cell morphology, as described above. Mean of three experiments+ S.D. ****p < 0.001 compared to untreated control cells (determined
by a two-tailed, unpaired t-test).
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Consistent with this, H3K27Ac peaks also declined on the
chromatin of many c-Myc target genes (Figs. S2B, C). ChIP-
Seq analysis following LSD1-KO also increased H3K27Ac
and BRD4 peaks at the enhancer-promoter regions of GFI1
gene (Fig. S2D), accompanied by increased GFI1 levels in
OCI-AML5 cells (Fig. 1A). RNA-Seq analysis following
LSD1-KO revealed the heat map of the up- or down-
regulated mRNAs (Fig. 2C), which included perturbations
of PU.1 and CEBPα target-gene expressions (Fig. S2E, F)33.
Gene set enrichment analyses (GSEA) of the perturbed
mRNAs, according to GO and HALLMARK pathways,
demonstrated significant positive normalized enrichment
scores (NES) for gene-sets, including those of innate
immune and inflammatory responses, apoptosis pathways,
but negative NES for c-Myc, WNT-β-catenin and
translation–initiation pathway genes (Figs. 2D and S2G).
Utilizing two custom-designed, nonoverlapping primer sets
and qPCR analysis, we also determined enhancer RNA
(eRNA) abundance within the known enhancer regions in
the MYC SE33. LSD1-KO in OCI-AML5 cells depleted
Fig. 2 Knockout of LSD1 alters chromatin accessibility, augments H3K27Ac occupancy on PU.1 target and WNT-β-Catenin target genes,
and knockout of GFI1 induces myeloid differentiation genes, LY96 and ITGAM (CD11b) and morphologic differentiation of AML cells. A
Log2 fold-change in H3K27Ac ChIP-Seq peaks (TSS+ 3 kb or gene body+ 10 kb) for PU.1 target genes (from the MSigDB database) in LSD1 knockout
compared to Cas9-only-expressing OCI-AML5 cells. B Log2 fold-change in H3K27Ac ChIP-Seq peaks (TSS+ 3 kb or gene body+ 10 kb) in WNT-
β-Catenin target genes (from HALLMARK datasets in the MSigDB database) in LSD1 knockout compared to Cas9-only-expressing OCI-AML5 cells. C
RNA-Seq analysis was performed on OCI-AML5 LSD1 knockout (biologic triplicates) and Cas9-only-expressing (biologic duplicates) cells 8 days post-
transduction. Heat map shows the number of mRNAs depleted or induced > 1.25-fold and p-value < 0.05 in the LSD1 knockout versus Cas9-only-
expressing cells. D Gene set enrichment analysis was performed with RNA expression changes in OCI-AML5 LSD1-KO cells compared to GO
pathways. The q-values are < 0.1 in all comparisons. E Representative immunoblot analysis of OCI-AML5 Cas9-expressing cells transduced with two
lentiviral sgRNAs against GFI1 and incubated for 8 days. F Relative mRNA expression analysis of OCI-AML5 GFI1 knockout cells compared to Cas9-
only-expressing cells. GAPDH expression was utilized as the normalization control. G Expression of CD11b (assessed by flow cytometry) in OCI-AML5-
Cas9 and GFI1 knockout cells 8 days post-transduction. Mean of two independent experiments performed in duplicate+ S.D. Significance
determined by a two-tailed, unpaired t-test. H Morphologic differentiation (% myelocytes and metamyelocytes or bands by morphologic features of
hematoxylin & eosin-stained cytospun cells) of OCI-AML5 GFI1 knockout cells compared to Cas9-only-expressing cells 8 days post-transduction. Mean
of two independent experiments performed in duplicate+ S.D. Significance determined by a two-tailed, unpaired t-test in GraphPad V8.
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eRNA expression from enhancers 3, 4, and 5 but not from
enhancer 2 of MYC (Fig. S2H).
Biologic outcome following depletion of GFI1 versus LSD1
in AML cells
Next, we compared effects of LSD1-KO with those of
GFI1 knockout in OCI-AML5 cells. Utilizing two gRNAs
designed against exon 2 and 3, CRISPR-Cas9-mediated
knockout of GFI1 in OCI-AML5 cells resulted in marked
depletion of GFI1, but not of LSD1, with concomitant
increase in mRNA expressions of ITGAM, CD86, LY96 and
LYZ, as well as increased PU.1, p21 and CD11b protein
levels with significant increase in % of cells displaying
morphologic differentiation (% increase in myelocytes and
metamyelocytes) and expressing CD11b (Fig. 2E–H). Thus,
similar to LSD1-KO, GFI1-KO also induced differentiation
of AML cells. To compare gene-expression perturbations
that accompany differentiation effects due to depletion of
LSD1 versus GFI1, we conducted knockdown (KD) of GFI1
and LSD1 with 2 shRNA each, which also exhibited similar
effects on differentiation and associated gene expressions in
OCI-AML5 (Figs. S3A, B, S4A–F, and data not shown).
Following treatment of OCI-AML5 cells with the shRNAs,
RNA-Seq analyses showed that considerably greater num-
bers of mRNA were up or downregulated by LSD1 versus
GFI1 shRNAs (Fig. S4G, H). LSD1-KD was associated with
global increases in the histone H3K4Me2 and H3K4Me3
levels, as well as increased mRNA expressions of PU.1 and
GFI1 targets, along with increased mRNA and/or protein
expressions of GFI1, PU.1, p21, p27, CD11b, LY96 and
CD86, but depletion of c-Myc (Figs. S4A–F, and S4I).
Similar effects following LSD1-KD by shRNAs were also
observed in AML MOLM13 cells expressing the MLL-AF9
fusion gene (S4J i–iv. and data not shown). Following KD of
GFI1 or LSD1, GSEA of the RNA-seq-determined mRNA
expression signatures also demonstrated positive NES for
gene-sets including those of interferon α & γ, TNFα, IL2- or
IL6-JAK-STAT3/5 and inflammatory pathway, while
negative NES were observed for gene-sets including those
of oxidative phosphorylation (Fig. S5A). In contrast, nega-
tive NESs included those for DNA repair, WNT-β-catenin,
MYC and E2F pathway gene-sets, but only in the RNA-Seq
signature of LSD1-KD (Fig. S5A). The Venn diagram in Fig.
S5B demonstrates considerably more nonoverlapping, up-
or downregulated gene-expressions following LSD1-KD,
whereas Fig. S5C shows a number of gene expressions that
were common and similarly perturbed, including those of
known PU.1 targets13,28, following either LSD1 or GFI1 KD.
The upregulation of PU.1 targets shown in Figure S5C is
likely due to both increased expression of PU.1 and inhi-
bition of GFI1-LSD1 axis. Overall, treatment with
LSD1 shRNA induced a higher % of differentiation than
GFI1 shRNA in OCI-AML5 cells, as determined by increase
in % CD11b expression (LSD1 shRNA: 68.7% versus
GFI1 shRNA: 30.4%) and morphologic features of myeloid
differentiation (LSD1 shRNA: 71.7% and GFI1 shRNA:
33.9%). This suggests that the amount of differentiation
induced by knockdown or knockout of LSD1 or GFI1 in
AML cells best correlated with increased expression of PU.1
and p21 but depletion of c-Myc. Notably, 96 h post treat-
ment with shRNA to LSD1 or GFI1, a small (<20%) but
similar % of apoptotic OCI-AML5 cells were observed (%
annexin V-positive cells).
LSD1 inhibitors disrupt binding of LSD1 to CoREST and
GFI1, inducing GFI1 levels, differentiation and cell lethality
in AML cells
We next determined effects of the tranylcypromine ana-
log, irreversible LSD1 I inhibitors (LSD1i) INCB059872
(INCB) and ORY-1001 in AML and post-MPN sAML
cells25,35–37. Co-immunoprecipitation (Co-IP) analyses
demonstrated that treatment with INCB reduced binding of
LSD1 with CoREST in the AML OCI-AML5, THP1, and in
sAML SET-2 cells (Fig. 3A–C)25. Sandwich ELISA
demonstrated that treatment with INCB decreased binding
of LSD1 with GFI1 in the AML cells (Fig. 3D). This was
associated with increase in protein levels of GFI1/1B and
PU.1 and decline in c-Myc, without significant alterations in
CoREST and LSD1 levels in the same cell lysates used for
the Co-IP analyses (Fig. 3A–C, and data not shown). INCB
treatment inhibited % colony growth of several AML (OCI-
AML5, THP1 and OCI-AML2) and post-MPN sAML cell
types (SET-2 and HEL92.1.7) (Fig. 3E, F), as well as
increased % of AML cells expressing CD11b and CD86 (Fig.
3G, H). Exposure to ORY-1001 exerted similar effects in
AML and sAML cells (Fig. S6A–F)25. To evaluate whether
LSD1i induces differentiation in AML cells solely by dis-
rupting interaction of LSD1 with GFI1, we determined the
effects of KD of GFI1 with or without co-treatment with the
LSD1i INCB. Fig. S7A–C demonstrate that treatment with
INCB significantly enhanced morphologic differentiation
induced by GFI1-KD in OCI-AML5 cells, associated with
increased % of cells expressing CD11b and CD86 (p < 0.05).
Although GFI1-KD blocked INCB-induced GFI1 levels,
INCB treatment increased differentiation with greater
decline in c-Myc and c-Myb levels (Fig. S7D). INCB treat-
ment also augmented GFI1 KD-induced p21 and CD11b
levels in OCI-AML5 cells (Fig. S7D). A similar effect of
INCB treatment on CD11b induction due to GFI1-KO via
CRISPR-Cas9 was also noted in OCI-AML5 cells (p < 0.01)
(Fig. S7E). These findings suggest that although clearly a
marker of LSD1i-induced AML differentiation, accom-
panying GFI1 induction is not mechanistically involved in
AML cell differentiation due to LSD1i-mediated disruption
of LSD1 and GFI1 interaction. They also suggest that both
scaffold and enzymatic functions of LSD1, which are
inhibited by INCB, may be involved in AML cell differ-
entiation induced by INCB38.
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LSD1 inhibitor-mediated early alterations in epigenome/
transcriptome in AML and post-MPN sAML cells
Since effects of LSD1-KD (utilizing shRNA) or LSD1-
KO (via CRISPR-Cas9) on epigenome/transcriptome can
only be evaluated several days after gene-editing, we next
determined whether these effects also occur soon after a
16-h exposure of AML and post-MPN sAML cells to
INCB. Following INCB treatment, ATAC-Seq analysis
demonstrated large numbers of lost and gained peaks,
including those gained in the bivalent poised enhancers,
enhancers, active TSS (transcription start sites) and
polycomb-repressed chromatin of OCI-AML5 cells (Fig.
S8A, B)39,40. TF motifs in the open chromatin included
those of CTCF, FOSL1, PU.1, RUNX1, IRF8 and c-Myc,
and the gained peaks included those in GFI1 and PU.1-
target genes (Fig. S8C–F). Similar gain of ATAC-seq
peaks were also noted in INCB-treated SET-2 cells (Fig.
S8G, H). Although H3K27Ac ChIP-seq analysis showed
only a slight increase in H3K27Ac signal-tag density at
active enhancers, ROSE plot highlighted active SEs of
RUNX1, GFI1, BCL2, PU.1, IRF8 and SMYD3 in INCB-
treated compared to untreated OCI-AML5 cells, accom-
panied by increased H3K27Ac occupancy at the chro-
matin of GFI1 and PU.1 target genes (Fig. S8I–K).
Notably, INCB treatment also increased BRD4 occupancy
at +/− 3 kb of TSSs, and especially at the GFI1 and PU.1-
target genes (Fig. S8L–N). RNA-Seq analysis showed that
INCB treatment up- and downregulated large numbers of
mRNA expressions, with positive NESs for gene-sets
including those for interferon α, inflammatory response
Fig. 3 Treatment with LSD1 inhibitor (LSD1i) disrupts binding of LSD1 to CoREST and GFI1, attenuates colony growth, and induces
differentiation in AML cells. A–C Immunoprecipitation and immunoblot analysis of OCI-AML5, THP1, and SET-2 cells treated with INCB059872 for
16 h. D Reduced binding of LSD1 and GFI1 (determined by sandwich ELISA assay) following 16 h of treatment with INCB059872. Mean of two
independent experiments performed in duplicate+ S.D. *p < 0.05, ***p < 0.005 (determined by a two-tailed, unpaired t-test). E, F OCI-AML5, OCI-
AML2, THP1, SET-2, and HEL92.1.7 cells were treated with the indicated concentrations of INCB059872 for 96 h. Then, cells were plated in Methocult
media and incubated at 37 °C. Colony growth was assessed after 7–10 days. Mean of two independent experiments+ S.D. G, H The % of CD86 and/
or CD11b-positive OCI-AML5, SET2 and HEL92.1.7 cells was determined by flow cytometry following treatment with INCB059872 for 96 h. Mean of
three experiments+ S.E.M. ***p < 0.005 in INCB059872-treated cells compared to untreated cells (determined by a two-tailed, unpaired t-test in
GraphPad V8).
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and E2F-target genes, and negative NES for c-Myc-targets
and oxidative phosphorylation gene-sets (Fig. S9A, B).
INCB treatment also positively enriched for GFI1-targets,
while negatively enriching for c-Myc targets (Fig. S9C, D).
Similar positive or negative NESs for these gene sets were
also noted for INCB-treated SET-2 cells (Fig. S9E).
Compared to untreated, RNA-Seq analyses of INCB-
treated OCI-AML5 and SET-2 cells also demonstrated
increased mRNA expressions of GFI1, PU.1, and CEBPα
target-genes (Fig. S9F–K). The target genes induced were
different in OCI-AML5 versus SET2 cells, most likely
because of their disparate cell biology due to their de novo
AML versus post-MPN sAML derivation. Notably,
although LSD1i treatment induced GFI1 expression,
because it disrupted binding of CoREST-LSD1 to GFI1,
LSD1i treatment prevented GFI1-mediated repression,
causing derepression of GFI1 target genes associated with
AML cell differentiation.
Targetable dependencies detected by protein domain-
focused CRISPR-Cas9 screen in LSD1i-treated versus
untreated AML cells
Utilizing a previously validated, GFP-tagged gRNA library
(1390 gRNAs and ~8 gRNA per gene) (Table S1) targeting
chromatin regulators transduced into OCI-AML5 cells that
stably expressed Cas9, we next conducted a protein
domain-focused CRISPR-Cas9 screen to nominate potential
drug targets in INCB-treated and untreated OCI-AML5
cells41. Eight days after transduction of gRNAs, cells were
treated or untreated with INCB (250 nM) for 4 days. NGS
was performed to determine negative selection of the
gRNAs identified on day 12 in INCB-treated versus
untreated OCI-AML5 cells, compared to the gRNA profile
sequenced on day-2 following transduction of gRNAs41. Fig.
S10 demonstrates the decline in % of GFP-positive cells
noted on day-12 compared to day-2, with the fold
sequencing coverage of guide RNAs maintained above
~400X (data not shown). Fig. 4A demonstrates the loss in
gRNA reads targeting specific genes, including LSD1,
BRD4, DOT1L, HDAC3, and MOZ. Based on this, we next
determined the lethal effect of doxycycline-inducible BRD4
shRNA-mediated BRD4 KD in AML cells that were co-
treated with INCB. Figure 4B, C demonstrate that BRD4
KD significantly increased INCB-induced CD11b and
apoptosis of OCI-AML5 cells. As previously reported,
treatment with the BETi OTX015 dose-dependently
induced apoptosis in OCI-AML5 cells expressing LSD1-
FKBP12F36V, which was significantly enhanced by LSD1
degradation following dTAG-13 treatment (Fig. 4D)10. In
this setting, the effect of co-treatment with dTAG-13 on
differentiation was not discernable. OTX015-induced
apoptosis was also significantly enhanced by CRISPR-
Cas9-mediated LSD1-KO in the post-MPN sAML SET-2
cells (Fig. 4E). ChIP-seq analysis demonstrated that,
compared to control, OTX015 treatment caused down-
regulation of BRD4 occupancy at enhancers/promoters of
genes, including MYC, CDK6, BCL2, MYB, PU.1, RUNX1,
TCF7L2, and GFI1 (Fig. 4F). Consistent with this, OTX015
treatment depleted mRNA expressions of these genes, but
induced mRNA levels of p21, ITGAM, LYZ, and LY96 (Fig.
S11A, and data not shown). Exposure to OTX015 also
repressed LSD1, GFI1, c-Myc, c-Myb, and PU.1, while
inducing p21 and p27 protein levels in OCI-AML5 and
SET-2 cells (Fig. S11B, D, E). OTX015 represses c-Myc and
as a result represses LSD1––a target of c-Myc42. Co-
treatment with INCB enhanced effects of OTX015 on
specific mRNAs, decreasing CDK6 and MYC but increasing
LY96, LYZ, ITGAM, and p21, as well as augmented effects
on protein-expressions, reducing c-Myc, c-Myb, GFI1, and
PU.1 but increasing levels of p21 and p27 in OCI-AML5
and SET-2 cells (Fig. S11A, D, E).
Co-inhibition of GFI1/LSD1 and BRD4, HDAC3, MOZ, or
DOT1L induces synergistic lethality in AML and post-MPN
sAML cells
We next determined in vitro lethal effects of co-
inhibition of LSD1 and the codependencies discovered by
the CRISPR-Cas9 screen. Co-treatment with INCB and
OTX015 or ABBV-075, a potent BETi43, synergistically
induced apoptosis in the indicated AML and sAML cell
lines with diverse genetic alterations documented by NGS
(Figs. S11C, S12A, B). Differentiation due to the combi-
nation was not observed (data not shown). Similarly,
ORY1001 and OTX015 treatment also exerted synergistic
lethality (Fig. S11F). Whereas modestly effective alone, co-
treatment with the HDAC3 inhibitor RGFP96644
(≥2.5 µM) and LSD1 depletion by dTAG-13 induced more
differentiation, not apoptosis, than either drug-treatment
alone (Fig. S13A and data not shown). Combined treat-
ment with INCB and RGFP966 induced synergistic leth-
ality in sAML SET2 while enhancing differentiation in
OCI-AML5 cells (Bliss synergy scores >5) (Fig. S13B–E).
Treatment with the MOZ inhibitor WM1119
(100–1000 nM) alone was also only modestly effective
(Fig. S14A)45, but co-treatment with dTAG-13 induced
significantly more differentiation (Fig. S14A) (p < 0.05).
Co-treatment with INCB and WM1119 exerted similar
effects as INCB and RGFP966 in the AML and sAML cells
(Bliss synergy score >5.0 or CI values <1.0) (Fig. S14B–F).
Consistent with the CRISPR screen result that DOT1L
HMTase is a codependency with INCB treatment, co-
treatment with INCB and the DOT1L inhibitor
EPZ5676 synergistically induced lethality in AML and
sAML cells (Fig. S15A)46. As also recently reported, we
discovered that co-treatment with an LSD1i (INCB or
ORY1001) and a DNA hypomethylating agent (decita-
bine) synergistically induced loss of viability in AML cells
(Fig. S15B, C)25.
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Next, we evaluated the lethal activity of LSD1i and BETi
in patient-derived (PD) AML blasts with genetic altera-
tions documented by NGS (Fig. S12C). We determined
that co-treatment with INCB and OTX015 for 48 h
induced synergistic loss of viability in 14 samples of AML
blasts (Fig. 5A). Exposure to INCB (250 nM for 16 h)
reduced mRNA and protein levels of c-Myc, while
inducing levels of GFI1, PU.1, ITGAM, (and LY96
mRNA) in PD AML blasts (Fig. 5B, C). In contrast,
treatment with OTX015 did not induce mRNA or protein
levels encoded by these genes, but attenuated MYC
expression in the PD AML blasts (Fig. 5B, C). Co-
treatment with INCB and OTX015 induced synergistic
loss of viability in 22 samples of PD, post-MPN sAML
Fig. 4 Synthetic lethal activity of treatment with INCB059872 and a CRISPR-Cas9-mediated domain-focused epigenetically targeted sgRNA
library in AML cells. A OCI-AML5 Cas9 cells were transduced with a library of domain-specific sgRNAs against chromatin modifying proteins and
incubated for 8 days. Then, 250 nM of INCB059872 was added and the cells were incubated for an additional 96 h. Live cells were harvested; genomic
DNA was isolated and minimally amplified with primers flanking the sgRNA sequences. Sequencing libraries were generated and amplicon-seq was
performed. The graph shows log2 fold-changes in selected sgRNAs which dropped out more due to treatment with INCB059872 than control cells at
day 12 post-transduction. B OCI-AML5 cells with stable expression of DOX-inducible BRD4 shRNA were induced with DOX and treated with the
indicated concentrations of INCB059872 for 96 h. Following this, the % of CD11b cells was determined by flow cytometry. Mean of two independent
experiments+ S.D. **p < 0.01, ***p < 0.005 as determined by a two-tailed, unpaired t-test. C OCI-AML5 cells with stable expression of DOX-inducible
BRD4 shRNA were induced with DOX and then treated with the indicated concentrations of INCB059872 for 96 h. Following this, the % of annexin V-
positive, apoptotic cells were determined by flow cytometry. Mean of two independent experiments+ S.D. *p < 0.05 as determined by a two-tailed,
unpaired t-test. D OCI-AML5 LSD1-FKBP12(F36V) cells were treated with the indicated concentrations of OTX015 with and without 500 nM of dTAG-13
for 48 h. Then, the % of To-Pro-3 iodide positive cells were determined by flow cytometry. Mean of three experiments+ S. E. M. *p < 0.05, **p < 0.01
compared to cells with no dTAG-13 treatment (determined by a two-tailed, unpaired t-test). E SET-2 cells were transfected with sgNeg or
LSD1 sgRNAs and incubated for 5 days. Then, cells were treated with the indicated concentrations of OTX015 for 48 h and the % of apoptotic cells
was determined by flow cytometry. Mean of two independent experiments performed in duplicate+ S.D. **p < 0.01, ***p < 0.005 relative to sgNeg-
transfected cells (determined by a two-tailed, unpaired t-test). F Log2 fold-changes in BRD4 peaks (determined by DiffReps analysis of BRD4 ChIP-Seq
data) on LSD1 target genes and selected AML-relevant genes in OCI-AML5 cells treated with 1000 nM of OTX015 for 8 h.
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Fig. 5 Co-treatment with LSD1i and BET inhibitor (BETi) or ruxolitinib exerts synergistic lethal activity in patient-derived AML and sAML
cells. A PD CD34+ AML blast cells (n= 14) were treated with INCB059872 (100–1000 nM) and/or OTX015 (dose range 250–1000 nM) for 48 h. The %
of To-Pro-3 iodide-positive, nonviable cells was determined by flow cytometry. Combination index values were calculated with CompuSyn.
Combination index values <1.0 indicate a synergistic interaction of the drugs in the combination. B PD, AML #6 blast cells were treated (in triplicate)
with INCB059872 or OTX015 as indicated. Total RNA was isolated, reverse transcribed and qPCR analysis was performed with TaqMan probes. The
relative mRNA expression of each target was normalized to GAPDH and compared to the untreated control. C PD AML #6 cells were treated with the
indicated concentrations of INCB059872 and/or OTX015 for 24 h. Total cell lysates were harvested and immunoblot analyses were conducted. The
expression levels of β-Actin in the lysates served as the loading control. D PD CD34+ post-MPN, sAML blast cells (n= 22) were treated with
INCB059872 (dose range: 100–1000 nM) and/or OTX015 (dose range 250–1000 nM) for 48 h. The % of To-Pro-3 iodide-positive, nonviable cells was
determined by flow cytometry. Combination index values were calculated with CompuSyn. Combination index values <1.0 indicate a synergistic
interaction of the drugs in the combination. E SET-2 cells transfected with sgNeg or LSD1 sgRNAs for 5 days were treated with the indicated
concentrations of ruxolitinib for 48 h. Then, the % of annexin V-positive, To-Pro-3 iodide-positive, apoptotic cells was determined by flow cytometry.
Mean of two independent experiments performed in duplicate+ S.D. ***p < 0.005 compared to sgNeg-transfected cells treated with ruxolitinib
(determined by a two-tailed, unpaired t-test). F SET-2, HEL92.1.7, and PD CD34+ post-MPN/MF sAML blast cells (n= 8) were treated with INCB059872
(100–1000 nM) and/or ruxolitinib (dose range 250–1000 nM) for 48 h. The % of annexin V-positive, apoptotic or To-Pro-3 iodide-positive, nonviable
cells was determined by flow cytometry. Combination index values were calculated with CompuSyn. Combination index values < 1.0 indicate a
synergistic interaction of the drugs in the combination. G HEL-RuxP and SET-2-RuxP cells were treated with the indicated concentrations of ruxolitinib
with or without 2 days of pre-treatment with 250 nM of INCB059872. The % of annexin V-positive, apoptotic cells was determined by flow cytometry.
Mean of three experiments+ S.E.M. ****p < 0.001 compared to cells without INCB059872 pre-treatment (determined by a two-tailed, unpaired t-test).
H PD, sAML blasts (n= 3) were treated with the indicated concentrations of ruxolitinib with or without 2 days of pre-treatment with 250 nM of
INCB059872 or 250 nM of ORY1001. Then, the % of To-Pro-3 iodide-positive, nonviable cells was determined by flow cytometry. ****p < 0.001
compared to cells without LSD1i pre-treatment (determined by a two-tailed, unpaired t-test). I PD, sAML (#20) cells transfected (in duplicate) with
sgNeg or LSD1 sgRNAs and incubated for 5 days were treated with the indicated concentrations of ruxolitinib for 48 h. The % of To-Pro-3 iodide-
positive, nonviable cells was determined by flow cytometry. ***p < 0.005 compared to sgNeg-transfected cells treated with ruxolitinib (determined by
a two-tailed, unpaired t-test). J Immunoblot analysis of PD, sAML (#20) 5 days posttransfection with sgNeg or LSD1 sgRNAs. K SET-2-RuxP and HEL-
RuxP cells were treated with INCB059872 (100–1000 nM) and/or OTX015 (dose range 250–1000 nM) for 48 h. The % of annexin V-positive, To-Pro-3
iodide-positive, apoptotic cells was determined by flow cytometry. Combination index values were calculated with CompuSyn. Combination index
values <1.0 indicate a synergistic interaction of the drugs in the combination.
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blasts (combination index values < 1.0) (Figs. 5D and
S12D). We also determined the effect of ruxolitinib in
sAML SET-2 cells with CRISPR-Cas9 mediated KO of
LSD1. As shown in Fig. 5E, ruxolitinib-induced apoptosis
was significantly augmented in SET-2 cells with LSD1-KO
(p < 0.005). Co-treatment with INCB and ruxolitinib also
synergistically induced lethality in HEL92.1.7 and SET-2,
as well as in samples of PD post-MPN sAML blasts in
which genetic mutations were documented by NGS (CI
values < 1.0) (Figs. 5F and S12D). Notably, in previously
described nongenetic ruxolitinib-persister/resistant
HEL92.1.7-RuxP and SET-2-RuxP cells, unlike in parental
SET-2 or HEL92.1.7 cells, pre-treatment with INCB for
48 h, markedly enhanced ruxolitinib-induced apoptosis in
HEL-RuxP and SET-2-RuxP cells (p < 0.001) (Fig. 5G)47.
Pre-treatment with INCB or ORY1001 for 48 h, sensitized
ruxolitinib-resistant PD CD34+ blast progenitor cells
(3 samples) to ruxolitinib-induced loss of cell viability
(Fig. 5H). Additionally, as shown in Fig. 5I, in a short-term
in vitro culture of PD, post-MPN sAML progenitor cells
(sAML#20), LSD1-KO via CRISPR-Cas9 significantly
enhanced ruxolitinib-induced lethality (p < 0.01). In
sAML#20, CRISPR-Cas9-mediated LSD1-KO depleted
protein levels of LSD1, CoREST and c-Myc, but increased
GFI1, GATA2, CEBPα, p21, and CD11b, without altering
protein levels of HDACs1/2 (Fig. 5J). These studies sug-
gest that co-treatment with LSD1i and ruxolitinib might
overcome development of nongenetic ruxolitinib resis-
tance in post-MPN sAML cells48. Co-treatment with
INCB and the BETi OTX015 also exerted synergistic
lethality in HEL-RuxP and SET-2-RuxP cells (CI values
<1.0) (Fig. 5K).
Pretreatment with LSD1i overcomes nongenetic BETi-
resistance in AML and post-MPN sAML blasts
We recently described BETi-persister/resistant (BETi-
P/R) post-MPN sAML and AML cells (SET-2-OTX P/R,
HEL-OTX P/R, and THP1-OTX P/R cells) that displayed
nongenetic mechanism of BETi-resistance, based on
increased expression and activity of β-catenin-TCF7L2-
JMJD6-c-Myc (Fig. S16A)33. Exposure to INCB for 96 h
dose-dependently induced differentiation and apoptosis
to a similar level in SET-2 and SET-2-OTX P/R as well as
HEL92.1.7 and HEL-OTX P/R cells, although exposure to
INCB for 48 h was relatively inactive in inducing apop-
tosis (Figs. 6A, B, and S16B). However, pretreatment with
INCB for 48 h, significantly increased BETi-induced
apoptosis in SET-2-OTX P/R, HEL-OTX P/R and
THP1-OTX P/R cells (Fig. 6C). Pretreatment with ORY-
1001 had a similar effect in sensitizing BETi-P/R cells to
BETi-induced apoptosis (Fig. S16C, D). In SET-2-OTX P/
R cells, qPCR analyses demonstrated that, compared to
treatment with INCB alone, pretreatment with INCB
followed by OTX015 caused inhibition of mRNA
expressions GFI1, TCF7L2, JMJD6, MYC, ITGAM, LY96,
BCL2, and BCL2L1 but increased p21 mRNA levels (Fig.
S16E). Western analyses showed that pretreatment with
INCB followed by OTX015 caused abrogation of GFI1,
TCF7L2, and PU.1 induced by INCB treatment alone,
with significant decline in c-Myc and JMJD6 but increase
in p27 levels (Fig. 6D). A significant increase in OTX015-
induced lethality was also observed following pretreat-
ment with INCB of PD AML and sAML blasts (Fig. 6E, F).
Similar to a recent report, we also determined the effects
of INCB pretreatment on chromatin accessibility and
potential enhancer reprogramming that could explain
sensitization to BETi49, by conducting ATAC-Seq and
RNA-Seq analyses in INCB-treated versus -untreated
SET-2 OTX P/R cells. INCB treatment caused increases
in ATAC-Seq peaks in the chromatin of GFI1, PU.1, and
IRF8 target genes (Fig. S17A–C). Consistent with this,
RNA-Seq analysis also showed increases in mRNA
expressions of GFI1, PU.1, and CEBPα target genes, with
concomitant decline in mRNAs of several MYC-target
genes (Fig. S17D–G). These findings highlight that INCB
pretreatment potentially commissions enhancers of GFI1,
PU.1, IRF8, and MYC genes and their targets to sensitize
BETi-P/R sAML cells to BETi-induced lethality.
In vivo efficacy of combination of LSD1i with ruxolitinib or
BETi against post-MPN sAML cells
Given the marked in vitro synergy noted above, we
determined in vivo antileukemia efficacy of INCB alone or
co-treatment with ruxolitinib or OTX015 in NSG mice
engrafted with AML or post-MPN sAML cells. Treatment
with INCB alone for 3–4 weeks reduced AML and sAML
burden and significantly improved overall survival of NSG
mice engrafted with OCI-AML5 or HEL92.1.7 cells,
respectively (Figs. 7A, B, S18A, B). Additionally, compared
to ruxolitinib alone, which did not favorably affect sAML
burden or the NSG mice survival, co-treatment with
INCB and ruxolitinib significantly reduced sAML burden
and improved overall survival of the NSG mice engrafted
with HEL92.1.7 cell (Fig. 7C, D). Next, we determined
effect of co-treatment with LSD1i on in vivo efficacy of
BETi in NSG mice engrafted with BETi-sensitive or BETi-
resistant sAML cells. Compared to monotherapy with
OTX015, combined therapy with INCB and OTX015 for
3 weeks significantly reduced sAML burden and improved
survival of NSG mice engrafted with BETi-sensitive
HEL92.1.7 cells without causing weight loss or other
signs of host toxicity (Fig. 7E, F, and data not shown).
Notably, co-treatment with INCB and OTX015 also sig-
nificantly reduced sAML burden and improved overall
survival of NSG mice engrafted with BETi-resistant HEL-
OTX P/R cells, again without resulting in any weight loss
or host toxicity (Fig. 7G, H and data not shown). These
findings suggest that combined therapy with LSD1i and
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BETi may exert in vivo efficacy and overcome nongenetic
BETi-P/R in post-MPN sAML cells.
Discussion
Utilizing the dTAG system to degrade LSD1 and
CRISPR-Cas9 to edit and KO LSD1, findings presented
here highlight gene-expression perturbations that lead to
differentiation of AML and post-MPN sAML blasts. Also,
disruption of LSD1 interactions with CoREST-HDAC1/2
complex and with GFI1/1B by LSD1i activates GFI1/1B-
repressed enhancers and transcription factors, including
PU.1, CEBPα and IRF8 while repressing c-Myc, and their
target gene-expressions. This induces cell cycle inhibitors
including p21 and p27, up-regulates differentiation-asso-
ciated gene-expressions such as CD11b, CD86, LY96, and
LYZ, and induces morphologic features of AML cell dif-
ferentiation. Although LSD1i inhibits both the scaffold and
enzymatic functions of LSD1, AML cell-differentiation
occurs independent of inhibiting enzymatic demethylase
function of LSD117,23,25,26,50. CRISPR-suppressor scanning
Fig. 6 LSD1i pre-treatment sensitizes BETi persister/resistant post-MPN sAML and de novo AML cells to BETi. A HEL92.1.7, HEL-OTX P/R, SET-2
and SET-2-OTX P/R cells were treated with INCB059872 for 96 h. The % of annexin V-positive, To-Pro-3 iodide-positive, apoptotic cells was determined
by flow cytometry. Mean of three experiments+ S.D. B SET-2-OTX P/R cells were treated with the indicated concentrations of INCB059872 for 96 h.
Differentiated cells were assessed by CD11b flow cytometry and by cell morphology. Mean of three experiments+ S.D. C SET-2-OTX P/R, HEL-OTX P/
R, and THP1-OTX P/R cells were treated with the indicated concentrations of OTX015 with or without 2 days of pre-treatment with 250 nM of
INCB059872. The % of annexin V-positive, apoptotic cells was determined by flow cytometry. Mean of three experiments+ S.D. ***p < 0.005, ****p <
0.001 compared to cells treated with OTX015 without INCB059872 pre-treatment (determined by a two-tailed, unpaired t-test). D Immunoblot
analyses conducted on total cell lysates from SET-2 and SET-2-OTX P/R cells pre-treated with INCB059872 (48 h) and/or OTX015 (24 h), as indicated.
E PD, sAML (#14) cells (ex vivo resistant to OTX015) were treated (in duplicate) with the indicated concentrations of OTX015 with or without 2 days of
pre-treatment with 250 nM of INCB059872. The % of To-Pro-3 iodide-positive, nonviable cells was determined by flow cytometry. *p < 0.05 compared
to cells treated with OTX015 without INCB059872 pre-treatment (determined by a two-tailed, unpaired t-test). F PD, AML (#8) blast cells (ex vivo
resistant to OTX015) were treated (in duplicate) with the indicated concentrations of OTX015 with or without 2 days of pre-treatment with 250 nM of
INCB059872. The % of To-Pro-3 iodide-positive, nonviable cells was determined by flow cytometry. ****p < 0.001 versus cells treated with OTX015
without INCB059872 pretreatment (determined by a two-tailed, unpaired t-test).
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was utilized to show that LSD1 enzyme activity is not
required for AML survival26. Instead, LSD1 inhibitors
disrupt interaction between LSD1 and transcription
repressor GFI1/1B on the chromatin. Also, in a knock-
down and rescue experiment, the LSD1 K661A catalytic
mutant was as capable of rescuing the clonogenic potential
of LSD1 knockdown cells as the wild type LSD1 pro-
tein23,50. Additionally, LSD1 inhibitor treatment induces
rapid and extensive transcriptional alterations, which do
not correlate with LSD1i-mediated changes in H3K4
mono- and dimethyl-chromatin marks23,50.
Additional findings highlighted here are that disruption
of LSD1-CoREST-HDAC1/2 complex derepresses GFI1/
1B SE/Es to cause early induction of GFI1/1B47, which
could serve as a predictive early biomarker of achieving
biologically effective intracellular levels of LSD1i in AML
and post-MPN sAML cells. LSD1-KO also increased
H3K27Ac and BRD4 occupancy at the GFI1 locus
Fig. 7 Treatment with INCB059872 and ruxolitinib or OTX015 reduced leukemia burden and improved survival of NSG mice engrafted
with sAML xenografts. A Total photon counts [flux] (determined by bioluminescent imaging) in NSG mice engrafted with OCI-AML5 GFP-Luc cells
and treated for 2 weeks with INCB059872. B Kaplan–Meier survival plot of NSG mice engrafted with OCI-AML5 GFP-Luc cells and treated with 1.5 mg/
kg of INCB059872 (daily x 5 days, P.O.) for 4 weeks. Significance was calculated by a Mantel–Cox log-rank test. C Total photon counts [flux] in NSG
mice engrafted with HEL92.1.7 GFP-Luc cells and treated for 2 weeks with INCB059872 and/or ruxolitinib. D Kaplan–Meier survival plot of NSG mice
engrafted with HEL92.1.7 GFP-Luc cells and treated with 1.5 mg/kg of INCB059872 (daily x 5 days, P.O.) and/or 20 mg/kg of ruxolitinib (daily x 5 days,
P.O.) for 3 weeks. Significance calculated by Mantel–Cox log-rank test. E Total photon counts [flux] in NSG mice engrafted with HEL92.1.7 GFP-Luc
cells and treated for 2 weeks with INCB059872 and/or OTX015. F Kaplan–Meier survival plot of NSG mice engrafted with HEL92.1.7 GFP-Luc cells and
treated with 1.5 mg/kg of INCB059872 (daily x 5 days, P.O.) and/or 30 mg/kg of OTX015 (daily x 5 days, P.O.) for 3 weeks. Significance calculated by
Mantel–Cox log-rank test. G Total photon counts [flux] in NSG mice engrafted with HEL-OTX P/R GFP-Luc cells and treated for 1 week with
INCB059872 followed by two weeks of INCB059872 and/or OTX015. *p < 0.05 (determined by a two-tailed, unpaired t-test). H Kaplan–Meier survival
plot of NSG mice engrafted with HEL-OTX P/R GFP-Luc cells and treated with 1.5 mg/kg of INCB059872 (daily x 5 days, P.O.) alone for 1 week,
followed by 3 weeks of 1.5 mg/kg of INCB059872 (daily x 5 days, P.O.) and/or 50 mg/kg OTX015 (daily x 5 days, P.O.). Significance was calculated by a
Mantel–Cox log-rank test.
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inducing GFI1 in AML cells. However, it is noteworthy
that without intact LSD1-CoREST-HDAC1/2 complex,
upregulated GFI1/1B is unable to repress differentiation
in AML/sAML cells19,21. Studies presented here also
involved CRISPR-Cas9-mediated KO of LSD1 or shRNA-
mediated KD of LSD1, which showed induction of GFI1/
1B, as well as of PU.1, CEBPα, and p21, but repression of
c-Myc in both post-MPN-sAML and non-MPN asso-
ciated AML cells. Notably, reduced H3K27Ac occupancy
at the MYC, but increased at the ITGAM, LY96, and LYZ
loci, induced ITGAM, LY96, and LYZ expressions, dif-
ferentiation and cell lethality of AML and post-MPN
sAML blasts. Our findings also confirmed that CRISPR-
Cas9-mediated GFI1-KO or shRNA-mediated GFI1-KD
also induced differentiation markers and morphologic
features of differentiation in AML cells, albeit to a lesser
extent than knockout or knockdown of LSD1. However,
these findings also demonstrated that LSD1i treatment
augmented differentiation due to GFI1-KD. This suggests
that disruption of LSD1 binding to repressive complexes
not involving GFI1/1B may also be contributing to LSD1i-
induced differentiation in AML cells17,18,51. Alternatively,
it also suggests that both scaffold and enzymatic functions
of LSD1 (inhibited by INCB) may be involved in AML cell
differentiation induced by INCB38. Again, LSD1i-induced
differentiation was also associated with induction of GFI1,
PU.1, and p21, but depletion of c-Myc in both post-MPN-
sAML and non-MPN associated AML cells. This high-
lights targeted degradation and depletion of LSD1, which
would disrupt both scaffolding and enzymatic activities of
LSD1, as an attractive therapeutic approach. Notably,
LSD1-KO decreased H3K27Ac occupancy at enhancers/
promoters and mRNA expressions of MYC and WNT-
β-catenin-target genes, associated with positive enrich-
ment of HALLMARK gene-sets of innate immunity,
inflammatory response and apoptosis in AML cells.
LSD1-KD by shRNA also positively enriched similar
HALLMARK gene-sets in AML cells. These findings are
consistent with recent reports that LSD1i treatment sti-
mulates antitumor immunity by inhibiting Foxp3+ Treg
cell function, thus enabling and enhancing immune
checkpoint blockade52,53. Collectively, these findings
highlight testing potential utility of including LSD1i co-
treatment with immune therapies in AML.
Utilizing a protein domain-focused CRISPR-
Cas9 screen, our studies revealed that BRD4, DOT1L,
HDAC3 and MOZ could serve as effective co-targets to
achieve synergistic efficacy with LSD1i against AML and
sAML cells. Consistent with this, LSD1i and BETi co-
treatment exhibited synergistic loss of viability in PD
AML and post-MPN sAML blasts displaying diverse
genetic alterations. In addition to abrogating LSD1i-
induced GFI1 and PU.1, BRD4 inhibition by BETi
increased lethal activity of LSD1i most likely due to
observed greater decline in c-Myc and increased p21 and
p27 protein levels. Additionally, in previous reports, we
have highlighted that inclusion of BETi enhances lethal
activity of BETi-based combinations due to greater
depletion of c-Myc, cell cycle dependent kinases CDK4
and CDK6, as well as concomitant induction of CDK
inhibitor p21, pro-apoptotic (BIM) and downregulation of
anti-apoptotic (MCL1, BCL-xL, and BCL2) pro-
teins.33,43,54–56. Synergistic in vitro lethality was also
observed due to co-treatment with LSD1i and agents
targeting HDAC3, MOZ or DOT1L. However, whether
these LSD1i-based combinations would also exert super-
ior in vivo anti-AML or anti-sAML efficacy remains to be
determined. Notably, a dual class I HDACi and LSD1
inhibitor was shown to exert synergistic lethality in AML
as well as in tumor models other than AML30,57,58.
CRISPR-Cas9 screens in AML cells expressing MLL-
fusion gene showed superior efficacy of co-targeting
mTORC1 with LSD1, which was not revealed by our
screen59. This difference is because our domain-focused
CRISPR-Cas9 screen involved AML cells without MLL
fusion gene-expression, and utilized gRNAs targeting
chromatin regulators not mTORC1. Our findings also
demonstrate that co-treatment with LSD1i and the JAK1/
2 inhibitor ruxolitinib exerts synergistic in vitro lethality
and exhibited superior in vivo efficacy than LSD1i
monotherapy in a mouse xenograft model of post-MPN
sAML. A recent report highlighted that LSD1i treatment
exhibited clinical efficacy by reducing spleen size and
constitutional symptoms in patients with advanced MPN,
thus combination therapy with LSD1i and JAKi merits
further in vivo evaluation60. Our studies demonstrating
synergistic in vitro lethality due to combination of LSD1i
with decitabine also merits further verification through
in vivo AML xenograft studies.
There is a growing evidence and recognition of epige-
netic heterogeneity and plasticity in cancer cells, which
under selection pressure of targeted therapies facilitates
emergence of drug-tolerant persister/resistant cancer cells
displaying nongenetic therapy-resistance61–63. Agents that
target signaling kinases (e.g., JAK1/2) and epigenetic
mechanisms (e.g., BET proteins) were shown to result in
enhancer reprogramming via newly-marshaled activities of
lineage-specific transcriptional regulators which creates
the transcriptome/proteome conferring drug tolerant
persister/resistance in AML cells33,48,49. We previously
reported that increased c-Myc expression due to increased
levels and activity of β-catenin-TCF7L2-JMJD6-MYC axis
induced nongenetic BETi-persister/resistance in AML and
sAML blasts33. This was due to enhancer reprogramming
and increased transcriptional activities of MYC, RUNX1,
and TCF7L2, based on H3K27Ac and BRD4 occupancy at
their Es/promoters33. Our findings demonstrate, for the
first time, that LSD1i is as active in inducing differentiation
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and lethality in the BETi-P/R as in BETi-sensitive sAML
cells. Notably, sensitization of BETi-P/R sAML and AML
cells to BETi-induced apoptosis by pre-treatment with
LSD1i was associated with increased chromatin accessi-
bility and mRNA expressions of GFI1, PU.1, and IRF8-
target genes. However, mRNA expressions of c-Myc tar-
gets were mostly downregulated. Importantly, our findings
also show that LSD1i pre-treatment similarly sensitized
sAML-RuxP cells that display nongenetic resistance to
ruxolitinib48. Taken together, these findings highlight that,
by reprogramming of SEs/Es and modifying gene-
expressions involved in conferring nongenetic persister/
resistance, LSD1i treatment could sensitize AML to BETi,
and sAML cells to ruxolitinib or BETi, thereby high-
lighting novel differentiation and lethal therapies for AML
or post-MPN sAML. Findings presented here also beg the
question where in AML or post-MPN sAML therapy
LSD1i-based combinations should best be clinically tested
for their efficacy, i.e., during induction therapy or during
consolidation therapy to effectively eliminate the MRD.
Due to their demonstrable ability to induce differentiation
and eliminate AML blast progenitors, as well as in aug-
menting immune checkpoint blockade therapy, LSD1i-
based combinations should be likely best tested for efficacy
in patients with AML in CR but detectable MRD that
eventually relapses as therapy-refractory AML.
Materials and methods
Cell lines and cell culture
OCI-AML5, OCI-AML2, Mono-Mac-1, MOLM13,
SKM-1, and SET-2 cells cells were obtained from the
DSMZ. MV4-11, HEL92.1.7, THP1, and HS5 cells were
obtained from the ATCC (Manassas, VA). HEK-293T cells
were obtained from the Characterized Cell Line Core
(CCLC) at M.D. Anderson Cancer Center, Houston TX.
Experiments with cell lines were performed within
6 months after thawing or obtaining from ATCC or DSMZ.
Cell lines were authenticated in the CCLC at M.D.
Anderson Cancer Center. Logarithmically growing,
mycoplasma-negative cells were utilized for all experiments.
Assessment of apoptosis by annexin-V staining
Untreated or drug-treated cells were stained with
Annexin-V (Pharmingen, San Diego, CA) and TO-PRO-3
iodide (Life Technologies, Carlsbad, CA) and the % of
apoptotic cells were determined by flow cytometry. To
analyze synergism, cells were treated with combinations
for 48 h and the % of apoptotic or nonviable cells were
determined by flow cytometry. The combination index
(CI) for each drug combination was calculated utilizing
CompuSyn software. We also utilized matrix dosing of
agents in combinations to allow synergy assessment by
Bliss scores utilizing the SynergyFinder online web
application tool.
RNA isolation and quantitative polymerase chain reaction
Following the designated treatments, total RNA was
isolated from AML or sAML cells utilizing a PureLink
RNAMini kit from Ambion, Inc. (Austin, TX) and reverse
transcribed. Quantitative real time PCR analysis was
performed on cDNA using TaqMan probes. Relative
mRNA expression was normalized to GAPDH and com-
pared to the untreated cells.
Statistical analysis
Significant differences between AML or sAML cells
treated with different experimental conditions compared
to control cells were determined using the two-tailed,
unpaired t-test. For the in vivo mouse models, a two-tailed,
unpaired t-test was utilized for comparing total biolumi-
nescent flux. For survival analysis, a Kaplan–Meier plot
and a Mantel–Cox log rank test were utilized for com-
parisons of different cohorts. P values of <0.05 were
assigned significance.
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